Why are there inconsistencies in the outcomes of some omega-3 fatty acid trials for the management of cardiovascular disease?

Clinical Lipidology

Volumn 10, Issue 1, 2015, Pages 27-32

  Shaikh, Nisar A ^a   Tappia, Paramjit S ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST BONIFACE GENERAL HOSPITAL   (Canada)

Author keywords

cardiovascular disease; clinical trials; meta analyses; omega 3 polyunsaturated fatty acids; outcomes

Indexed keywords

AMIODARONE; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; OLIVE OIL; OMEGA 3 FATTY ACID; PLACEBO;

ANTIARRHYTHMIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG FORMULATION; FAT INTAKE; FISH; HEART ARREST; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK REDUCTION; SUDDEN CARDIAC DEATH;

EID: 84924126328     PISSN: 17584299     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.15.1     Document Type: Note

References (47)

1. Sinclair HM. The diet of Canadian eskimos. Proc. Nutr. Soc. 12, 69-82 (1953).
2. Bang HO, Dyerber J, Sinclair HM. The composition of the Eskimo food in north western Greenland. Am. J. Clin. Nutr. 33, 2657-2661 (1980).
3. Bang HO, Dyerberg J, Nielsen AB. Plasma lipid and lipoprotein pattern in Greenlandic west-coast eskimos. Lancet 1, 1143-1145 (1971).
4. Bjerregaard P, Dyerberg J. Mortality from ischaemic heart disease and cerebrovascular disease in Greenland. Int. J. Epidemiol. 17, 514-519 (1988).
5. Newman WP, Middaugh JP, Propst MT, Rogers DR. Atherosclerosis in Alaska natives and non-natives. Lancet 341, 1056-1057 (1993).
6. Ruxton CHS, Reed SC, Simpson MJA, Millington KJ. The health benefits of omega-3 polyunsaturated fatty acids: a review of the evidence. J. Hum. Nutr. Diet. 17, 449-459 (2004).
7. Sijben JW, Calder PC. Differential immunomodulation with long-chain n-3 PUFA in health and chronic disease. Proc. Nutr. Soc. 66, 237-259 (2007).
8. Grimble RF, Tappia PS. Modulation of pro-inflammatory cytokine biology by unsaturated fatty acids. Z. Ernahrungswiss. 37, 57-65 (1998).
9. Grimble RF, Tappia PS. Modulatory influence of unsaturated fatty acids on the biology of tumour necrosis factor-alpha. Biochem. Soc. Trans. 23, 282-287 (1995).
10. Lauritzen L, Hansen HS, Jørgensen MH, Michaelsen KF. The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. Prog. Lipid Res. 40, 1-94 (2001).
11. Xu YJ, Gregor T, Dhalla NS, Tappia PS. Is the jury still out on the benefits of fish, seal and flax oils in cardiovascular disease. Ann. Nutr. Disord. Ther. 1, 40 (2014).
12. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N. Engl. J. Med. 312, 1205-1209 (1985).
13. Burr ML, Fehily AM, Gilbert JF et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet 2, 757-761 (1989).
14. Siscovick DS, Raghunathan TE, King I et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. J. Am. Med. Assoc. 274, 1363-1367 (1995).
15. Albert CM, Campos H, Stampfer MJ et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N. Engl. J. Med. 346, 1113-1118 (2002).
16. Mozaffarian D, Lemaitre RN, King IB et al. Plasma phospholipid long-chain omega-3 fatty acids and total and cause-specific mortality in older adults: a cohort study. Ann. Intern. Med. 158, 515-525 (2013).
17. Mozaffarian D, Lemaitre RN, King IB et al. Circulating long-chain omega-3 fatty acids and incidence of congestive heart failure in older adults: the cardiovascular health study: a cohort study. Ann. Intern. Med. 155, 160-170 (2011).
18. Bays HE, Ballantyne CM, Kastelein JJ et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the multicenter, placebo-controlled, randomized, double-blind, 12-week study with an open-label extension [MARINE] trial). Am. J. Cardiol. 108, 682-690 (2011).
19. Harris WS, Ginsberg HN, Arunakul N et al. Safety and efficacy of omacor in severe hypertriglyceridemia. J. Cardiovasc. Risk 4, 385-391 (1997).
20. Shaikh NA, Yantha J, Shaikh S et al. Efficacy of a unique omega-3 formulation on the correction of nutritional deficiency and its effects on cardiovascular disease risk factors in a randomized controlled VASCAZEN® REVEAL Trial. Mol. Cell. Biochem. 396, 9-22 (2014).
21. GISSI Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano Per Lo Studio Della Sopravvivenza Nell'infarto miocardico. Lancet 354, 447-455 (1999).
22. Yokoyama M, Origasa H, Matsuzaki M et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded end point analysis. Lancet 369, 1090-1098 (2007).
23. Tavazzi L, Maggioni AP, Marchioli R et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 372, 1223-1230 (2008).
24. Burr ML, Ashfield WP, Dunstan FDJ et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur. J. Clin. Nutr. 57, 193-200 (2003).
25. Brouwer IA, Zock PL, Camm AJ et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. J. Am. Med. Assoc. 295, 2613-2619 (2006).
26. Rauch B, Schiele R, Schneider S et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 122, 2152-2159 (2010).
27. Kromhout D, Giltay EJ, Geleijnse JM. Alpha Omega Trial Group. N-3 fatty acids and cardiovascular events after myocardial infarction. N. Engl. J. Med. 363, 2015-2026 (2010).
28. Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am. J. Med. 112, 298-304 (2002).
29. Hooper L, Thompson RL, Harrison RA et al. Risks and benefits of omega-3 fats for mortality, cardiovascular disease, and cancer: systematic review. Br. Med. J. 332, 752-760 (2006).
30. Marik PE, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin. Cardiol. 32, 365-372 (2009).
31. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. J. Am. Med. Assoc. 308, 1024-1033 (2012).
32. Lewis EJH. Omega-3 fatty acid supplementation and cardiovascular disease events [letter]. J. Am. Med. Assoc. 309, 27 (2013).
33. Vlachopoulos C, Richter D, Stefanadis C. Omega-3 fatty acid supplementation and cardiovascular disease events. J. Am. Med. Assoc. 309, 28 (2013).
34. Kwak SM, Myung SK, Lee YJ, Seo HG. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch. Intern. Med. 172, 686-694 (2012).
35. León H, Shibata MC, Sivakumaran S et al. Effect of fish oil on arrhythmias and mortality: systematic review. Br. Med. J. 337, a2931 (2008).
36. Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F. Long chain omega-3 fatty acids and cardiovascular disease: a systematic review. Br. J. Nutr. 107(Suppl. 2), S201-S213 (2012).
37. Sekikawa A, Curb JD, Ueshima H et al. Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study. J. Am. Coll. Cardiol. 52, 417-424 (2008).
38. Shaikh NA, Downar E, Butany J. Amiodarone - an inhibitor of phospholipase activity: a comparative study of the inhibitory effects of amiodarone, chloroquine and chlorpromazine. Mol. Cell. Biochem. 76, 163-172 (1987).
39. Calder PC. The role of marine omega-3 (n-3) fatty acids in inflammatory processes, atherosclerosis and plaque stability. Mol. Nutr. Food. Res. 56, 1073-1080 (2012).
40. Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation 88, 523-533 (1993).
41. Cawood AL, Ding R, Napper FL et al. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis 212, 252-259 (2010).
42. Covas MI. Olive oil and the cardiovascular system. Pharmacol. Res. 55, 175-186 (2007).
43. Estruch R, Ros E. Eat a healthy diet and drink wisely to postpone dying if you survived a myocardial infarction? Yes, but randomized clinical trials are needed. JAMA Intern. Med. 173, 1819-1820 (2013).
44. Shaikh NA, Shaikh S, Yantha J, Jackowski G. Differential uptake of omega-3 polyunsaturated fatty acids in trial subjects could explain variability of the trials' outcome. Circulation 130, A20243 (2014).
45. Pishva H, Mahboob SA, Mehdipour P et al. Fatty acid-binding protein-2 genotype influences lipid and lipoprotein response to eicosapentaenoic acid supplementation in hypertriglyceridemic subjects. Nutrition 26, 1117-1121 (2010).
46. Olano-Martin E, Anil E, Caslake MJ et al. Contribution of apolipoprotein E genotype and docosahexaenoic acid to the LDL-cholesterol response to fish oil. Atherosclerosis 209, 104-110 (2010).
47. Kris-Etherton PM, Harris WS, Appel LJ. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler. Thromb. Vasc. Biol. 23, 151-152 (2003).